The city of Tampa, Florida, currently has 16 active clinical trials seeking participants for Alzheimer's Disease research studies.
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/04/2024
Locations: Tampa General Hospital, Tampa, Florida
Conditions: Alzheimer Disease
Register for Updates
Study of AV-1959, an Amyloid Beta Vaccine
NCT05642429
Recruiting
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/08/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Alzheimer Disease
Register for Updates
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Register for Updates
Preventing Alzheimer's With Cognitive Training
NCT03848312
Recruiting
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residentia... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
11/21/2022
Locations: University of South Florida, Tampa, Florida
Conditions: Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
Register for Updates